Education
About Us
Working with TipRanks
Follow Us
Xilio Therapeutics (XLO)
NASDAQ:XLO
Total Valuation
Xilio Therapeutics has a market cap or net worth of $35.73M. The enterprise value is -$44.28M.
Market Cap$35.73M
Enterprise Value-$44.28M
Share Statistics
Xilio Therapeutics has 51,782,272 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,782,272
Owned by Insiders18.26%
Owned by Institutions1.29%
Financial Efficiency
Xilio Therapeutics’s return on equity (ROE) is -3.31 and return on invested capital (ROIC) is -134.62%.
Return on Equity (ROE)-3.31
Return on Assets (ROA)-0.82
Return on Invested Capital (ROIC)-134.62%
Return on Capital Employed (ROCE)-1.38
Revenue Per Employee99.13K
Profits Per Employee-910.02K
Employee Count64
Asset Turnover0.09
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio5.00
Price to Fair Value2.90
Price to FCF1.76
Price to Operating Cash Flow2.54
PEG Ratio-0.04
Income Statement
In the last 12 months, Xilio Therapeutics had revenue of 6.34M and earned -58.24M in profits. Earnings per share was -1.09.
Revenue6.34M
Gross Profit6.34M
Operating Income-60.58M
Pretax Income-58.24M
Net Income-58.24M
EBITDA-58.00M
Earnings Per Share (EPS)-1.09
Cash Flow
In the last 12 months, operating cash flow was 21.10M and capital expenditures -58.00K, giving a free cash flow of 21.04M billion.
Operating Cash Flow21.10M
Free Cash Flow21.04M
Free Cash Flow per Share0.41
Dividends & Yields
Xilio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.08
52-Week Price Change-28.57%
50-Day Moving Average0.74
200-Day Moving Average0.87
Relative Strength Index (RSI)46.96
Average Volume (3m)371.79K
Important Dates
Xilio Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Xilio Therapeutics as a current ratio of 2.21, with Debt / Equity ratio of 73.50%
Current Ratio2.21
Quick Ratio2.21
Debt to Market Cap0.16
Net Debt to EBITDA0.83
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Xilio Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Xilio Therapeutics EV to EBITDA ratio is -0.07, with an EV/FCF ratio of -0.21.
EV to Sales0.62
EV to EBITDA-0.07
EV to Free Cash Flow-0.21
EV to Operating Cash Flow-0.22
Balance Sheet
Xilio Therapeutics has $89.07M in cash and marketable securities with $7.86M in debt, giving a net cash position of -$81.21M billion.
Cash & Marketable Securities$89.07M
Total Debt$7.86M
Net Cash-$81.21M
Net Cash Per Share-$1.57
Tangible Book Value Per Share$0.33
Margins
Gross margin is 58.82%, with operating margin of -954.95%, and net profit margin of -918.05%.
Gross Margin58.82%
Operating Margin-954.95%
Pretax Margin-918.05%
Net Profit Margin-918.05%
EBITDA Margin-890.56%
EBIT Margin-940.18%
Analyst Forecast
The average price target for Xilio Therapeutics is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.00
Price Target Upside614.29% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast53.92%